"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.
As part of the Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the many ways in which BCG has improved the management of patients with bladder cancer. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.